• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Childhood Multisystem Inflammatory Syndrome — A New Challenge in the Pandemic

Mary Wilson

Well-known member
Michael Levin, F.Med.Sci., Ph.D.
June 29, 2020
DOI: 10.1056/NEJMe2023158

The recognition and description of new diseases often resemble the parable of the blind men and the elephant, with each declaring that the part of the beast they have touched fully defines it. As the coronavirus disease 2019 (Covid-19) pandemic has evolved, case reports have appeared describing children with unusual febrile illnesses that have features of Kawasaki’s disease,[SUP]1[/SUP] toxic shock syndrome,[SUP]2[/SUP] acute abdominal conditions, and encephalopathy, along with other reports of children with fever, elevated inflammatory markers, and multisystem involvement.[SUP]3-5[/SUP] It is now apparent that these reports were describing different clinical presentations of a new childhood inflammatory disorder.

The published reports have used a variety of hastily developed case definitions based on the most severe cases, possibly missing less serious cases. The CDC and WHO definitions require evidence of SARS-CoV-2 infection or exposure — a requirement that is problematic, since asymptomatic infections are common and antibody testing is neither universally available nor reliable.

Overall, a consistent clinical picture is emerging. MIS-C occurs 2 to 4 weeks after infection with SARS-CoV-2. The disorder is uncommon (2 in 100,000 persons <21 years of age) as compared with SARS-CoV-2 infection diagnosed in persons younger than 21 years of age over the same period (322 in 100,000).[SUP]7[/SUP]Most patients with MIS-C have antibodies against SARS-CoV-2, and virus is detected in a smaller proportion. A relatively high proportion of cases have occurred among black, Hispanic, or South Asian persons.[SUP]5-8[/SUP]

https://www.nejm.org/doi/full/10.1056/NEJMe2023158?source=nejmtwitter&medium=organic-social
 
Back
Top